Synthetic cannabinoid JWH-018 and psychosis: An explorative study
Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive...
Gespeichert in:
Veröffentlicht in: | Drug and alcohol dependence 2011-09, Vol.117 (2), p.152-157 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 157 |
---|---|
container_issue | 2 |
container_start_page | 152 |
container_title | Drug and alcohol dependence |
container_volume | 117 |
creator | Every-Palmer, Susanna |
description | Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids. |
doi_str_mv | 10.1016/j.drugalcdep.2011.01.012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902097083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871611000639</els_id><sourcerecordid>1093441292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQQCMEotvCX0C5ILhkmXGyjs0BaakoBVXiUBBHy7En1EvWSe2kIv8eR7tQiQNgjeTLmw_7TZblCGsE5K92axumb7ozloY1A8Q1LMEeZCsUtSwAKv4wW0FZ80LUyE-y0xh3kA6X8Dg7YVgiR85W2fZ69uMNjc7kRnuvG-d7Z_OPXy8LQJFrb_Mhzuamjy6-zrc-px9D1wc9ujvK4zjZ-Un2qNVdpKfH-yz7cvHu8_llcfXp_Yfz7VVhOGNjYaHWDW5a4o1hZFuNLUBT1ULWTWMrURlRynIjSZjGSCiZbm2FlQS7IU5tU55lLw51h9DfThRHtXfRUNdpT_0UlQQGsgZRJvLlX0ms09s3jKP4NwqyrCpkkiVUHFAT-hgDtWoIbq_DnCC1WFE7dW9FLVYULLGkPjt2mZo92d-JvzQk4PkR0NHorg3aGxfvuWWESvLEvT1wlD76zlFQ0TjyhqwLZEZle_c_07z5o4jpnHep73eaKe76KfgkUqGKTIG6XrZoWSLEZX-SpJ-pD8MV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1093441292</pqid></control><display><type>article</type><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Every-Palmer, Susanna</creator><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><description>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2011.01.012</identifier><identifier>PMID: 21316162</identifier><identifier>CODEN: DADEDV</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Addictive behaviors ; Adult ; Adult and adolescent clinical studies ; Anxiety ; Aroma ; Biological and medical sciences ; Cannabinoid receptors ; Cannabinoids ; Cannabinoids - adverse effects ; Cannabinoids - pharmacology ; Cannabis ; Designer drugs ; Dreams ; Drug abuse ; Drug addiction ; Drug dependence ; Drug tolerance ; Forensic psychiatry ; Forensic science ; Humans ; incense ; Indoles - adverse effects ; Indoles - pharmacology ; Interview, Psychological ; JWH-018 ; Legislation ; Male ; Medical sciences ; Mental disorders ; Middle Aged ; Naphthalenes - adverse effects ; Naphthalenes - pharmacology ; New Zealand ; Pharmacology ; Popularity ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Psychoses, substance-induced ; Psychoses, Substance-Induced - epidemiology ; Psychosis ; Psychotic disorders ; Psychotic Disorders - complications ; Psychotic Disorders - epidemiology ; Psychotic symptoms ; Qualitative research ; Receptor, Cannabinoid, CB1 - agonists ; Receptor, Cannabinoid, CB2 - agonists ; Relapse ; Risk factors ; Side effects ; Smoking ; Spice ; Spices ; Street Drugs - adverse effects ; Street Drugs - pharmacology ; Substance-Related Disorders - epidemiology ; Withdrawal ; Withdrawal symptoms ; Young Adult</subject><ispartof>Drug and alcohol dependence, 2011-09, Vol.117 (2), p.152-157</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</citedby><cites>FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2011.01.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,30981,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24412496$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21316162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</description><subject>Addictive behaviors</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Anxiety</subject><subject>Aroma</subject><subject>Biological and medical sciences</subject><subject>Cannabinoid receptors</subject><subject>Cannabinoids</subject><subject>Cannabinoids - adverse effects</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabis</subject><subject>Designer drugs</subject><subject>Dreams</subject><subject>Drug abuse</subject><subject>Drug addiction</subject><subject>Drug dependence</subject><subject>Drug tolerance</subject><subject>Forensic psychiatry</subject><subject>Forensic science</subject><subject>Humans</subject><subject>incense</subject><subject>Indoles - adverse effects</subject><subject>Indoles - pharmacology</subject><subject>Interview, Psychological</subject><subject>JWH-018</subject><subject>Legislation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Naphthalenes - adverse effects</subject><subject>Naphthalenes - pharmacology</subject><subject>New Zealand</subject><subject>Pharmacology</subject><subject>Popularity</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Psychoses, substance-induced</subject><subject>Psychoses, Substance-Induced - epidemiology</subject><subject>Psychosis</subject><subject>Psychotic disorders</subject><subject>Psychotic Disorders - complications</subject><subject>Psychotic Disorders - epidemiology</subject><subject>Psychotic symptoms</subject><subject>Qualitative research</subject><subject>Receptor, Cannabinoid, CB1 - agonists</subject><subject>Receptor, Cannabinoid, CB2 - agonists</subject><subject>Relapse</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Smoking</subject><subject>Spice</subject><subject>Spices</subject><subject>Street Drugs - adverse effects</subject><subject>Street Drugs - pharmacology</subject><subject>Substance-Related Disorders - epidemiology</subject><subject>Withdrawal</subject><subject>Withdrawal symptoms</subject><subject>Young Adult</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkk1v1DAQQCMEotvCX0C5ILhkmXGyjs0BaakoBVXiUBBHy7En1EvWSe2kIv8eR7tQiQNgjeTLmw_7TZblCGsE5K92axumb7ozloY1A8Q1LMEeZCsUtSwAKv4wW0FZ80LUyE-y0xh3kA6X8Dg7YVgiR85W2fZ69uMNjc7kRnuvG-d7Z_OPXy8LQJFrb_Mhzuamjy6-zrc-px9D1wc9ujvK4zjZ-Un2qNVdpKfH-yz7cvHu8_llcfXp_Yfz7VVhOGNjYaHWDW5a4o1hZFuNLUBT1ULWTWMrURlRynIjSZjGSCiZbm2FlQS7IU5tU55lLw51h9DfThRHtXfRUNdpT_0UlQQGsgZRJvLlX0ms09s3jKP4NwqyrCpkkiVUHFAT-hgDtWoIbq_DnCC1WFE7dW9FLVYULLGkPjt2mZo92d-JvzQk4PkR0NHorg3aGxfvuWWESvLEvT1wlD76zlFQ0TjyhqwLZEZle_c_07z5o4jpnHep73eaKe76KfgkUqGKTIG6XrZoWSLEZX-SpJ-pD8MV</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Every-Palmer, Susanna</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7QJ</scope></search><sort><creationdate>20110901</creationdate><title>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</title><author>Every-Palmer, Susanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c622t-d07ab15fe6bc2edfa1f00b47897bbd484c839359e8cbc9032afd41490d5e6efb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Addictive behaviors</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Anxiety</topic><topic>Aroma</topic><topic>Biological and medical sciences</topic><topic>Cannabinoid receptors</topic><topic>Cannabinoids</topic><topic>Cannabinoids - adverse effects</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabis</topic><topic>Designer drugs</topic><topic>Dreams</topic><topic>Drug abuse</topic><topic>Drug addiction</topic><topic>Drug dependence</topic><topic>Drug tolerance</topic><topic>Forensic psychiatry</topic><topic>Forensic science</topic><topic>Humans</topic><topic>incense</topic><topic>Indoles - adverse effects</topic><topic>Indoles - pharmacology</topic><topic>Interview, Psychological</topic><topic>JWH-018</topic><topic>Legislation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Naphthalenes - adverse effects</topic><topic>Naphthalenes - pharmacology</topic><topic>New Zealand</topic><topic>Pharmacology</topic><topic>Popularity</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Psychoses, substance-induced</topic><topic>Psychoses, Substance-Induced - epidemiology</topic><topic>Psychosis</topic><topic>Psychotic disorders</topic><topic>Psychotic Disorders - complications</topic><topic>Psychotic Disorders - epidemiology</topic><topic>Psychotic symptoms</topic><topic>Qualitative research</topic><topic>Receptor, Cannabinoid, CB1 - agonists</topic><topic>Receptor, Cannabinoid, CB2 - agonists</topic><topic>Relapse</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Smoking</topic><topic>Spice</topic><topic>Spices</topic><topic>Street Drugs - adverse effects</topic><topic>Street Drugs - pharmacology</topic><topic>Substance-Related Disorders - epidemiology</topic><topic>Withdrawal</topic><topic>Withdrawal symptoms</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Every-Palmer, Susanna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Every-Palmer, Susanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthetic cannabinoid JWH-018 and psychosis: An explorative study</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>117</volume><issue>2</issue><spage>152</spage><epage>157</epage><pages>152-157</pages><issn>0376-8716</issn><eissn>1879-0046</eissn><coden>DADEDV</coden><abstract>Abstract Background Aroma, Spice, K2 and Dream are examples of a class of new and increasingly popular recreational drugs. Ostensibly branded “herbal incense”, they have been intentionally adulterated with synthetic cannabinoids such as JWH-018 in order to confer on them cannabimimetic psychoactive properties while circumventing drug legislation. JWH-018 is a potent cannabinoid receptor agonist. Little is known about its pharmacology and toxicology in humans. This is the first research considering the effects of JWH-018 on a psychiatric population and exploring the relationship between JWH-018 and psychotic symptoms. Method This paper presents the results of semi-structured interviews regarding the use and effects of JWH-018 in 15 patients with serious mental illness in a New Zealand forensic and rehabilitative service. Results All 15 subjects were familiar with a locally available JWH-018 containing product called “Aroma” and 86% reported having used it. They credited the product's potent psychoactivity, legality, ready availability and non-detection in drug testing as reasons for its popularity, with most reporting it had replaced cannabis as their drug of choice. Most patients had assumed the product was “natural” and “safe”. Anxiety and psychotic symptoms were common after use, with 69% of users experiencing or exhibiting symptoms consistent with psychotic relapse after smoking JWH-018. Although psychological side effects were common, no one reported becoming physically unwell after using JWH-018. Three subjects described developing some tolerance to the product, but no one reported withdrawal symptoms. Conclusion It seems likely that JWH-018 can precipitate psychosis in vulnerable individuals. People with risk factors for psychosis should be counseled against using synthetic cannabinoids.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>21316162</pmid><doi>10.1016/j.drugalcdep.2011.01.012</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0376-8716 |
ispartof | Drug and alcohol dependence, 2011-09, Vol.117 (2), p.152-157 |
issn | 0376-8716 1879-0046 |
language | eng |
recordid | cdi_proquest_miscellaneous_902097083 |
source | MEDLINE; Elsevier ScienceDirect Journals; Applied Social Sciences Index & Abstracts (ASSIA) |
subjects | Addictive behaviors Adult Adult and adolescent clinical studies Anxiety Aroma Biological and medical sciences Cannabinoid receptors Cannabinoids Cannabinoids - adverse effects Cannabinoids - pharmacology Cannabis Designer drugs Dreams Drug abuse Drug addiction Drug dependence Drug tolerance Forensic psychiatry Forensic science Humans incense Indoles - adverse effects Indoles - pharmacology Interview, Psychological JWH-018 Legislation Male Medical sciences Mental disorders Middle Aged Naphthalenes - adverse effects Naphthalenes - pharmacology New Zealand Pharmacology Popularity Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Psychoses, substance-induced Psychoses, Substance-Induced - epidemiology Psychosis Psychotic disorders Psychotic Disorders - complications Psychotic Disorders - epidemiology Psychotic symptoms Qualitative research Receptor, Cannabinoid, CB1 - agonists Receptor, Cannabinoid, CB2 - agonists Relapse Risk factors Side effects Smoking Spice Spices Street Drugs - adverse effects Street Drugs - pharmacology Substance-Related Disorders - epidemiology Withdrawal Withdrawal symptoms Young Adult |
title | Synthetic cannabinoid JWH-018 and psychosis: An explorative study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthetic%20cannabinoid%20JWH-018%20and%20psychosis:%20An%20explorative%20study&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Every-Palmer,%20Susanna&rft.date=2011-09-01&rft.volume=117&rft.issue=2&rft.spage=152&rft.epage=157&rft.pages=152-157&rft.issn=0376-8716&rft.eissn=1879-0046&rft.coden=DADEDV&rft_id=info:doi/10.1016/j.drugalcdep.2011.01.012&rft_dat=%3Cproquest_cross%3E1093441292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1093441292&rft_id=info:pmid/21316162&rft_els_id=S0376871611000639&rfr_iscdi=true |